22nd Century Group to make further advances into cannabinoid production

US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production.

Announcing its full-year results for 2021, the company said it generated its first revenue from hemp/cannabis IP and plant lines in the fourth quarter of 2021.

Part of this came from a three-way non-exclusive licence of the Anandia biosynthesis IP (jointly owned with Aurora Cannabis) to Cronos Group, to assist in the advancement of biosynthetic cannabinoids


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo